Next Article in Journal
Resveratrol Counteracts Insulin Resistance—Potential Role of the Circulation
Previous Article in Journal
Biomarkers of Systemic Inflammation and Growth in Early Infancy are Associated with Stunting in Young Tanzanian Children
Open AccessArticle

Yeast-Derived Recombinant Avenanthramides Inhibit Proliferation, Migration and Epithelial Mesenchymal Transition of Colon Cancer Cells

1
Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy
2
CCM Italia research network (www.ccmitalia.unito.it), 10043 Torino, Italy
3
Department of Agriculture, Forest and Food Sciences, Plant Genetics and Breeding, University of Torino, 10095 Torino, Italy
4
Department of Life Sciences, University of Siena, 53100 Siena, Italy
5
Department of Clinical and Biological Sciences, University of Torino, 10043 Torino, Italy
*
Author to whom correspondence should be addressed.
These authors share senior authorship.
Nutrients 2018, 10(9), 1159; https://doi.org/10.3390/nu10091159
Received: 6 August 2018 / Revised: 20 August 2018 / Accepted: 22 August 2018 / Published: 24 August 2018
Avenanthramides (Avns), polyphenols found exclusively in oats, are emerging as promising therapeutic candidates for the treatment of several human diseases, including colon cancer. By engineering a Saccharomyces cerevisiae strain, we previously produced two novel phenolic compounds, N-(E)-p-coumaroyl-3-hydroxyanthranilic acid (Yeast avenanthramide I, YAvnI) and N-(E)-caffeoyl-3-hydroxyanthranilic acid (Yeast avenanthramide II, YAvnII), which are endowed with a structural similarity to bioactive oat avenanthramides and stronger antioxidant properties. In this study, we evaluated the ability of these yeast-derived recombinant avenanthramides to inhibit major hallmarks of colon cancer cells, including sustained proliferation, migration and epithelial-mesenchymal transition (EMT). Using the human colon adenocarcinoma cell line HT29, we compared the impact of YAvns and natural Avns, including Avn-A and Avn-C, on colon cancer cells by performing MTT, clonogenic, adhesion, migration, and anchorage-independent growth assays, and analyzing the expression of EMT markers. We found that both YAvns and Avns were able to inhibit colon cancer cell growth by increasing the expression of p21, p27 and p53 proteins. However, YAvns resulted more effective than natural compounds in inhibiting cancer cell migration and reverting major molecular features of the EMT process, including the down-regulation of E-cadherin mRNA and protein levels. View Full-Text
Keywords: nutraceuticals; polyphenols; oats avenanthramides; yeast-derived recombinant avenanthramides; colon cancer cells; proliferation; migration; epithelial-mesenchymal transition (EMT); chemoprevention nutraceuticals; polyphenols; oats avenanthramides; yeast-derived recombinant avenanthramides; colon cancer cells; proliferation; migration; epithelial-mesenchymal transition (EMT); chemoprevention
Show Figures

Figure 1

MDPI and ACS Style

Finetti, F.; Moglia, A.; Schiavo, I.; Donnini, S.; Berta, G.N.; Di Scipio, F.; Perrelli, A.; Fornelli, C.; Trabalzini, L.; Retta, S.F. Yeast-Derived Recombinant Avenanthramides Inhibit Proliferation, Migration and Epithelial Mesenchymal Transition of Colon Cancer Cells. Nutrients 2018, 10, 1159.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop